Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,489
archived clinical trials in
Endometrial Cancer

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated:  7/7/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated: 7/7/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated:  7/25/2015
Ohio State University-Division of Gyn Oncology
1960
mi
from 91732
Columbus, OH
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated: 7/25/2015
Ohio State University-Division of Gyn Oncology
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated:  8/3/2015
University of Arkansas
1463
mi
from 91732
Little Rock, AR
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
University of Arkansas
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated:  8/3/2015
University Hospital Case Medical Center
2036
mi
from 91732
Cleveland, OH
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
University Hospital Case Medical Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated:  8/3/2015
University of Texas
1228
mi
from 91732
Dallas, TX
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
University of Texas
1228
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated:  8/3/2015
University of Texas
1400
mi
from 91732
Galveston, TX
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
University of Texas
1400
mi
from 91732
Galveston, TX
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated:  8/3/2015
Eastern Virginia Medical School
2336
mi
from 91732
Norfolk, VA
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Eastern Virginia Medical School
2336
mi
from 91732
Norfolk, VA
Click here to add this to my saved trials
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated:  9/10/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Disseminated Endometrial Cancer Cells During Sonohysterography
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
1654
mi
from 91732
Madison, WI
Disseminated Endometrial Cancer Cells During Sonohysterography
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Sexual Functioning in Endometrial Cancer
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin School of Medicine and Public Health
1654
mi
from 91732
Madison, WI
Sexual Functioning in Endometrial Cancer
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin School of Medicine and Public Health
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated:  10/1/2015
Washington University School of Medicine
1570
mi
from 91732
St. Louis, MO
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated: 10/1/2015
Washington University School of Medicine
1570
mi
from 91732
St. Louis, MO
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Geauga Regional Hospital
2032
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Geauga Regional Hospital
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Lake/University Ireland Cancer Center
2044
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Lake/University Ireland Cancer Center
2044
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
University Suburban Health Center
2040
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
University Suburban Health Center
2040
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Chagrin Highlands Medical Center
2041
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Chagrin Highlands Medical Center
2041
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Southwest General Health Center
2028
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Southwest General Health Center
2028
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Westlake Medical Center
2020
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Westlake Medical Center
2020
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Mercy Cancer Center at Mercy Medical Center
2032
mi
from 91732
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Mercy Cancer Center at Mercy Medical Center
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated:  11/11/2015
Swedish Medical Center - Issaquah Campus
952
mi
from 91732
Issaquah, WA
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Swedish Medical Center - Issaquah Campus
952
mi
from 91732
Issaquah, WA
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated:  11/11/2015
Pacific Gynecology Specialists
961
mi
from 91732
Seattle, WA
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Pacific Gynecology Specialists
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated:  11/11/2015
Swedish Medical Center
961
mi
from 91732
Seattle, WA
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Swedish Medical Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated:  12/15/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated:  12/15/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
RAD001 in Recurrent Endometrial Cancer Patients
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated:  1/6/2016
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
RAD001 in Recurrent Endometrial Cancer Patients
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated: 1/6/2016
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Lymph Node Counts in Endometrial Cancer Staging
A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging
Status: Enrolling
Updated:  1/20/2016
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Lymph Node Counts in Endometrial Cancer Staging
A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging
Status: Enrolling
Updated: 1/20/2016
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Pinnacle Oncology Hematology
353
mi
from 91732
Scottsdale, AZ
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Pinnacle Oncology Hematology
353
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Comprehensive Blood and Cancer Center
105
mi
from 91732
Bakersfield, CA
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Comprehensive Blood and Cancer Center
105
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated:  2/3/2016
Dana-Farber Cancer Institue
2578
mi
from 91732
Boston, MA
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Dana-Farber Cancer Institue
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated:  3/10/2016
Albert Einstein Comprehensive Cancer Center
2440
mi
from 91732
Bronx, NY
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Albert Einstein Comprehensive Cancer Center
2440
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated:  3/10/2016
NYU School of Medicine's Kaplan Comprehensive Cancer Center
2434
mi
from 91732
New York, NY
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
NYU School of Medicine's Kaplan Comprehensive Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated:  3/10/2016
The New York Presbyterian Hospital - Cornell Campus
2434
mi
from 91732
New York, NY
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
The New York Presbyterian Hospital - Cornell Campus
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated:  3/10/2016
Mount Sinai Medical Center, NY
2435
mi
from 91732
New York, NY
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Mount Sinai Medical Center, NY
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated:  3/10/2016
New York Medical College
2443
mi
from 91732
Valhalla, NY
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
New York Medical College
2443
mi
from 91732
Valhalla, NY
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2053
mi
from 91732
Augusta, GA
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2053
mi
from 91732
Augusta, GA
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2376
mi
from 91732
Abington, PA
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2376
mi
from 91732
Abington, PA
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
31
mi
from 91732
Newport Beach, CA
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
31
mi
from 91732
Newport Beach, CA
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
1959
mi
from 91732
Columbus, OH
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
2562
mi
from 91732
Providence, RI
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated:  3/31/2016
Investigational Site Number 3212
5571
mi
from 91732
Kortrijk,
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Investigational Site Number 3212
5571
mi
from 91732
Kortrijk,
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
2435
mi
from 91732
New York, NY
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
827
mi
from 91732
Portland, OR
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials